GEOPOLMonitorGlobal Gene Therapy for Ovarian Cancer Pipeline Analysis Report 2018PR Newswire (press release)The report covers the present scenario and the growth prospects of the gene therapy for ovarian cancer for 2018-2022. To calculate the market si… Continue reading
OncLiveImmunotherapy in Advanced/Metastatic Gastric/GEJ CancersOncLiveZev A. Wainberg, MD: The role of immunotherapy in gastric cancer is based on the premise that, relative to a lot of other malignancies, gastric and GEJ cancers do have a good number … Continue reading
Genetic Engineering & Biotechnology NewsStem Cells Made into Relay Cells for Sense of TouchGenetic Engineering & Biotechnology NewsSensory interneurons have been derived from human embryonic stem cells and from human induced pluripotent stem cells, mar… Continue reading
BioPharma-Reporter.com |
Product characterisation key to successful CAR T therapies, Autolus
BioPharma-Reporter.com And speaking at last month’s Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam, Jim Faulkner, SVP and head of manufacturing at UK-based CAR T-cell therapy developer Autolus, said it was imperative to reduce the costs to allow such … |
FierceBiotech |
AveXis steps up gene therapy pursuit of Biogen’s SMA pathfinder
FierceBiotech AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) with a series of new trials as it plays catch-up with Biogen and Ionis, which claimed the first approval for an SMA drug. The Chicago biotech already has … AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular AtrophyMarkets Insider AveXis (NASDAQ:AVXS) PT Set at $122.00 by UBS GroupThe Lincolnian Online Chardan Capital Reiterates Buy Rating for AveXis (NASDAQ:AVXS)StockNewsTimes |